A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients

NCT02578641 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL: autologous EBV specific Cytotoxic T cells
DRUG: combination IV gemcitabine and IV carboplatin (AUC2)

Sponsor

Tessa Therapeutics